Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Offer Insights on Healthcare Companies: Pelthos Therapeutics (PTHS), Abbott Laboratories (ABT) and Pfizer (PFE)

Tipranks - Tipranks - Tue Apr 21, 7:22AM CDT

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Pelthos Therapeutics (PTHS), Abbott Laboratories (ABT) and Pfizer (PFE).

Claim 30% Off TipRanks

Pelthos Therapeutics (PTHS)

Alliance Global Partners analyst James Molloy reiterated a Buy rating on Pelthos Therapeutics today and set a price target of $75.00. The company’s shares closed last Friday at $23.02.

According to TipRanks.com, Molloy ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -21.7% and a 25.9% success rate. Molloy covers the Healthcare sector, focusing on stocks such as Reviva Pharmaceuticals Holdings, Neurosense Therapeutics Ltd., and Intensity Therapeutics, Inc. ;'>

Pelthos Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $57.14, implying a 145.8% upside from current levels. In a report released today, Piper Sandler also reiterated a Buy rating on the stock with a $48.00 price target.

See today’s best-performing stocks on TipRanks >>

Abbott Laboratories (ABT)

Mizuho Securities analyst Anthony Petrone maintained a Hold rating on Abbott Laboratories today and set a price target of $115.00. The company’s shares closed last Friday at $96.81.

According to TipRanks.com, Petrone is a 4-star analyst with an average return of 5.2% and a 49.6% success rate. Petrone covers the Healthcare sector, focusing on stocks such as GE Healthcare Technologies Inc, Establishment Labs Holdings, and Inspire Medical Systems. ;'>

Currently, the analyst consensus on Abbott Laboratories is a Strong Buy with an average price target of $126.53, a 32.3% upside from current levels. In a report issued on April 16, TipRanks – Google also downgraded the stock to Hold with a $110.00 price target.

Pfizer (PFE)

In a report released today, Trung Huynh from RBC Capital maintained a Sell rating on Pfizer, with a price target of $25.00. The company’s shares closed last Friday at $27.56.

According to TipRanks.com, Huynh is a 5-star analyst with an average return of 23.7% and a 73.1% success rate. Huynh covers the Healthcare sector, focusing on stocks such as Bristol-Myers Squibb, Merck & Company, and Eli Lilly & Co. ;'>

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Pfizer with a $29.47 average price target.

Read More on PTHS:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).